Abstract
It has long been accepted that high concentrations of glutamate can destroy neurons,and this is the basis of the theory of excitotoxicity during brain injury such as stroke.Glutamate N-methyl- D-aspartate (NMDA)receptor antagonists such as Selfotel,Aptiganel,Gavestinel and others failed to show neuroprotective efficacy in human clinical trials or produced intolerable central nervous system adverse effects.The failure of these agents has been attributed to poor studies in animal models and to poorly designed clinical trials.We also speculate that NMDA receptor anatagonism may have hindered endogenous mechanisms for neuronal survival and neuroregeneration.It remains to be proven in human stroke whether NMDA receptor antagonism can be neuroprotective.
Keywords: Ischemic Stroke, D-aspartate, glutamate, Aptiganel
Current Molecular Medicine
Title: The Rise and Fall of NMDA Antagonists for Ischemic Stroke
Volume: 4 Issue: 2
Author(s): L. Hoyte, P. A. Barber, A. M. Buchan and M. D. Hill
Affiliation:
Keywords: Ischemic Stroke, D-aspartate, glutamate, Aptiganel
Abstract: It has long been accepted that high concentrations of glutamate can destroy neurons,and this is the basis of the theory of excitotoxicity during brain injury such as stroke.Glutamate N-methyl- D-aspartate (NMDA)receptor antagonists such as Selfotel,Aptiganel,Gavestinel and others failed to show neuroprotective efficacy in human clinical trials or produced intolerable central nervous system adverse effects.The failure of these agents has been attributed to poor studies in animal models and to poorly designed clinical trials.We also speculate that NMDA receptor anatagonism may have hindered endogenous mechanisms for neuronal survival and neuroregeneration.It remains to be proven in human stroke whether NMDA receptor antagonism can be neuroprotective.
Export Options
About this article
Cite this article as:
Hoyte L., Barber A. P., Buchan M. A. and Hill D. M., The Rise and Fall of NMDA Antagonists for Ischemic Stroke, Current Molecular Medicine 2004; 4 (2) . https://dx.doi.org/10.2174/1566524043479248
DOI https://dx.doi.org/10.2174/1566524043479248 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From Discovery to Clinical Trials: Treatment Strategies for Central Neuropathic Pain after Spinal Cord Injury
Current Pharmaceutical Design Cucurbitacin E, An Experimental Lead Triterpenoid with Anticancer, Immunomodulatory and Novel Effects Against Degenerative Diseases. A Mini-Review
Current Topics in Medicinal Chemistry Epigenetic Changes in the Methylation Patterns of KCNQ1 and WT1 after a Weight Loss Intervention Program in Obese Stroke Patients
Current Neurovascular Research Microglial Proteases: Strategic Targets for Neuroprotective Agents
Current Neuropharmacology Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Opiate Drug Use and the Pathophysiology of NeuroAIDS
Current HIV Research Understanding The Role of Inflammasome in Angina Pectoris
Current Protein & Peptide Science Integrins as Therapeutic Targets for Respiratory Diseases
Current Molecular Medicine Nitrone Derivatives as Therapeutics: From Chemical Modification to Specific-targeting
Current Topics in Medicinal Chemistry Brivaracetam Prevents the Over-expression of Synaptic Vesicle Protein 2A and Rescues the Deficits of Hippocampal Long-term Potentiation In Vivo in Chronic Temporal Lobe Epilepsy Rats
Current Neurovascular Research Neuroprotection by Estrogen and Progesterone in Traumatic Brain Injury and Spinal Cord Injury
Current Neuropharmacology Improvement in Hypertension Management with Pharmacological and Non- Pharmacological Approaches: Current Perspectives
Current Pharmaceutical Design Quantitative Imaging Biomarkers and their Emerging Role
Current Medical Imaging Imaging Epigenetics in Alzheimer’s Disease
Current Pharmaceutical Design Frontier Lipid-Based Carrier Systems for Drug Targeting: A Laconic Review on Niosomes
Pharmaceutical Nanotechnology Functions of MAPR (Membrane-Associated Progesterone Receptor) Family Members As Heme/Steroid-Binding Proteins
Current Protein & Peptide Science Fluorescein Fluorescence Use in the Management of Intracranial Neoplastic and Vascular Lesions: A Review and Report of a New Technique
Current Drug Discovery Technologies Hematoma Expansion: Clinical and Molecular Predictors and Corresponding Pharmacological Treatment
Current Drug Targets Bone Marrow Derived Cells for Brain Repair: Recent Findings and Current Controversies
Current Molecular Medicine CT and MR Imaging of the Encephalopathic Child
Current Medical Imaging